1. Reconciled Ophthalmology and Sensory Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 936 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 295 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 438 / 95 | 17.82% closed-trial attrition ratio across 533 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 13 / 11 / 13 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 81.7% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Ophthalmology and Sensory
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| Shahid Beheshti University of Medical Sciences | Academic / Institutional Sponsor | 34 | 2 | 5 | 0 |
| Bausch Health | Biopharma Industry | 33 | 4 | 26 | 133 |
| Aldeyra Therapeutics | Biopharma Industry | 29 | 1 | 27 | 0 |
| Apellis Pharmaceuticals | Biopharma Industry | 19 | 4 | 12 | 0 |
| Dompé Farmaceutici S.p.A | Biopharma Industry | 19 | 4 | 8 | 0 |
| Glaukos | Biopharma Industry | 16 | 5 | 7 | 4 |
3. Representative Multi-Center Phase II & III Ophthalmology and Sensory Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT07740564 | Phase III Study of OT202 in Treating Moderate to Severe Dry Eye | Ocumension Therapeutics (Suzhou) Co | Phase III | RECRUITING |
| NCT06997874 | Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract Removal | Queen's University, Belfast | Phase III | RECRUITING |
| NCT07317934 | Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) | Innostellar Biotherapeutics Co | Phase III | RECRUITING |
| NCT06708156 | The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | Oupushifang Pharmaceutical Technology Co | Phase III | RECRUITING |
| NCT06753916 | ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty | Massachusetts Eye and Ear Infirmary | Phase II | RECRUITING |
| NCT07567040 | Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial | Ohio State University | Phase III | RECRUITING |
| NCT07395232 | An Efficacy and Safety Study of DFL24498 in the Treatment of AKC | Dompé Farmaceutici S.p.A | Phase III | RECRUITING |
| NCT06891443 | Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | Laboratoires Thea | Phase III | RECRUITING |
| NCT06847542 | A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD | Roche / Genentech | Phase III | RECRUITING |
| NCT07776522 | Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration | West China Hospital | Phase II | RECRUITING |
| NCT06213649 | Parasitic Ulcer Treatment Trial | Jeremy Keenan, MD, MPH | Phase III | RECRUITING |
| NCT05821959 | Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss | Eli Lilly and Company | Phase III | RECRUITING |
| NCT06659445 | Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD | ONL Therapeutics | Phase II | RECRUITING |
| NCT07519902 | An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED | Dompé Farmaceutici S.p.A | Phase III | RECRUITING |
| NCT07064759 | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 4D Molecular Therapeutics | Phase III | RECRUITING |
| NCT07441642 | A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration | Novartis | Phase II | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.